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Bone marrow (BM) metastasis remains one of the
main causes of death associated with solid tumors
as well as multiple myeloma (MM). Targeting the
BM niche to prevent or modulate metastasis has
not been successful to date. Here, we show that stro-
mal cell-derived factor-1 (SDF-1/CXCL12) is highly
expressed in active MM, as well as in BM sites of
tumor metastasis and report on the discovery of
the high-affinity anti-SDF-1 PEGylated mirror-image
L-oligonucleotide (olaptesed-pegol). In vivo confocal
imaging showed that SDF-1 levels are increased
withinMMcell-colonizedBMareas. Using in vivomu-
rine and xenograft mouse models, we document that
in vivo SDF-1 neutralization within BM niches leads
to a microenvironment that is less receptive for MM
cells and reduces MM cell homing and growth,
thereby inhibiting MM disease progression. Target-
ing of SDF-1 represents a valid strategy for prevent-
ing or disrupting colonization of the BM by MM cells.INTRODUCTION
Mechanisms that allow clonal multiple myeloma (MM) or solid
tumor cells to home to and colonize bone marrow (BM) sites
are not well defined. Seventy percent of patients with metastatic
breast or prostate cancer present with involvement of the BM,
and BM metastases also appear in about 15%–30% of patients
with colon, lung, stomach, thyroid, prostate, and kidney cancer
(Roodman, 2004). MM patients at diagnosis are characterized
by the presence of multiple BM-lytic lesions, which indicate
the perpetual dissemination of clonal plasma cells—originating
in the birthplace of the MM clone—to multiple BM niches
throughout the skeleton (Roodman, 2004); such lesions suggest
that BM niches form an optimal environment for the lodgment
and growth of MM cells. MM cells may also behave similarly to118 Cell Reports 9, 118–128, October 9, 2014 ª2014 The Authorshematopoietic stem cells (HSCs), explaining why MM cells
are selectively trafficked to BM sites (Karnoub and Weinberg,
2006–2007; Scadden, 2006; Smith et al., 2004). In fact, it has
been argued that clonal plasma cells—or other types of BM-
metastasizing tumor cells—use the same signals and molecules
that are critical for selection of the HSC niche: these include the
chemoattractant stromal-cell-derived factor-1 (SDF-1/CXCL12),
which is a major retention factor for HSCs and mature immune
cells in BM tissue (Scheiermann et al., 2013).
The biological effects of SDF-1 are related its ability to trigger
motility, chemotactic responses, adhesion, and the secretion of
matrix metalloproteinases and angiopoietic factors. The impor-
tance of SDF-1 is also reflected by its ability to activate integrins
such as LFA-1, VLA-4, and VLA-5 (expressed on HSCs), and to
thus promote adhesion and migration (Dar et al., 2006; Kucia
et al., 2005; Peled et al., 1999, 2000; Wysoczynski et al., 2005).
Other factors such as fibroblast growth factors, transforming
growth factor b, insulin-like growth factors I and II, platelet-
derived growth factors, and bone morphogenetic proteins also
contribute to the preferential homing of tumor cells to the BM.
And additionally, it is likely that areas of high blood flow in
red marrow facilitate tumor cell metastasis to these regions of
BM (Callander and Roodman, 2001; Chirgwin and Guise, 2000;
Roodman, 2004). Moreover, MM cells are characterized by
the presence of CXCR4 (one of the SDF-1 receptors), and
SDF-1-dependent signaling via CXCR4 plays a critical role in
regulating fundamental biological functions of MM cells, such
as migration and adhesion in vitro, as well as their homing to
the bone marrow in vivo (Alsayed et al., 2007; Azab et al.,
2009). SDF-1 also activates the CXCR7 receptor (Tarnowski
et al., 2010), which modulates trafficking and adhesion of human
malignant hematopoietic cells.
Collectively, these findings point to the importance of targeting
SDF-1, and of neutralizing CXCR4 and CXCR7, both of which are
expressed on tumor cells (Burwick et al., 2008; Miao et al., 2007;
Tarnowski et al., 2010; Xu et al., 2011). We reasoned that by
neutralizing SDF-1, we can change the BM milieu, create a
microenvironment that is less receptive for MM cells, diminish
the homing of MM cells to the BM, and thereby inhibit MM
disease progression. We report here on the discovery and char-
acterization of olaptesed pegol (ola-PEG), a high-affinity L-RNA
Spiegelmer to SDF-1, and we demonstrate that ola-PEG-medi-
ated neutralization of SDF-1 is a valid strategy for preventing
MM progression in vivo.
RESULTS
Metastatic Bone Marrow Niches Reveal Increased
Expression of SDF-1
Given the importance of SDF-1 in facilitating bone metastasis in
a variety of clonal tumor cells, we compared the expression of
this chemokine in the BM of patients with bone metastases
of solid tumors or of multiple myeloma (MM), to that in the BM
of healthy individuals or of patients with monoclonal gammop-
athy of undetermined significance (MGUS). Our findings indicate
that BM that is affected by colonization of solid tumor cells or
MM cells presents with higher expression of SDF-1, compared
to samples from healthy controls or from MGUS patients, which
showed scattered, minimal SDF-1 expression (Figure 1A). These
findings indicate the significance of SDF-1 in the BM niche of
metastatic tumors, including MM as a model of BM metastasis.
We next focused on corroborating the role of SDF-1 in facili-
tating the homing, lodgment, and growth of MM cells in vivo.
We used in vivo live confocal imaging to determine the localiza-
tion and spatial distribution of SDF-1 in BM niches that are occu-
pied byMM cells. By injecting a fluorescently labeled anti-SDF-1
in mice that harbor MM GFP+ tumors, we found that SDF-1 was
enriched in BM areas that were colonized by MM cells, whereas
SDF-1 was only observed within blood vessels in BM niches that
were free of MM cells (Figure 1B). This observation is consistent
with prior reports that transplanted hematopoietic stem and
progenitor cell populations localize in subdomains of BM micro-
vessels, where the SDF-1 chemokine is particularly abundant
(Colmone et al., 2008; Sipkins et al., 2005). The finding was
also supported by the significantly higher level of SDF-1 secreted
from primary BM-mesenchymal stromal cells (MSCs) that were
obtained fromMMpatients, relative to those that were harvested
from healthy subjects (Figure 1C). Taken together, these results
demonstrate that MM cells preferentially localized in SDF-1-
enriched BM niche.
To better define the functional role of MM BM-MSC-secreted
SDF-1 on MM cells, we used primary MM BM-MSCs to under-
take SDF-1 loss-of-function studies. Transduction and knock-
down efficiency of SDF-1 were evaluated with use of immunoflu-
orescence and ELISA, respectively (Figures S1A and S1B).
Results showed that knocking down the secretion of SDF-1
fromMMBM-MSCs inhibits the adhesion and also the migration
of MM cells toward primary MM BM-MSCs (Figures S1C and
S1D). Moreover, MM cells cultured in the presence of BM-
MSC cells in which SDF-1 was knocked down presented with
reduced activation of prosurvival and migration-related path-
ways (Figure S1E).
Identification of the SDF-1-Neutralizing Spiegelmer
Ola-Pegol
We identified a high-affinity, structured L-RNA oligonucleotide
(Spiegelmer) (Klussmann et al., 1996) that binds and inhibitsSDF-1. Initially, we applied an in vitro evolutionary screening
technology based on the SELEX process (Tuerk and Gold,
1990) to select aptamers from a pool of randomized RNA oligo-
nucleotides against D-SDF-1 (the enantiomer of natural L-SDF-1).
This process led to the identification of aptamer sequences,
which were synthesized as Spiegelmers by using nonnatural
L-ribonucleotides. The Spiegelmers were then able to bind to
natural L-SDF-1.
For in vitro selection against D-SDF-1, we used reiterative
rounds with increasing stringency and amplification steps that
included mutagenic PCR (in rounds 15 and 17; Figure S2A).
The enriched library from round 18 was cloned and sequenced.
An alignment revealed sequences that differed by point muta-
tions and by a nonrelated orphan sequence (Figure S2B). After
truncating the primer binding sites, the best aptamer (193-G2)
was trimmed to a 45-mer (193-G2-001) without loss of affinity
(Figure S2C). A pull-down assay showed that the binding of
193-G2-001 to D-SDF-1 resulted in a dissociation constant (KD)
of 268 pM at 37C (Figure 2A).
The RNA aptamer 193-G2-001 ola-PEG was converted into
its corresponding Spiegelmer. A secondary structure prediction
(mfold) is depicted in Figure 2B (Zuker, 2003). To slow down renal
clearance of the Spiegelmer, we increased its molecular weight
by conjugating a 40 kDa polyethylene glycol (PEG) to its 50 end.
This PEGylated L-RNA oligonucleotide was named 0p; all subse-
quent in vitro and in vivo data were generated with ola-PEG. KD
of approximately 200 pM to human andmouse SDF-1a/b/gwere
determined with use of surface plasmon resonance (Biacore) un-
der physiological conditions (Figure 2C; Table S1). Because the
3D structures of chemokines are conserved (Wells and Peitsch,
1997), we used a competitive assay format to test ola-PEG bind-
ing against a panel of 23 different chemokines. Other than solu-
ble SDF-1, none of the other chemokines could compete with
ola-PEG, demonstrating a high selectivity of ola-PEG to SDF-1
(Figure 3A).
In Vitro Functional Characterization of
Ola-PEG-Dependent Targeting of SDF-1
We evaluated the influence of SDF-1 on the expression of
CXCR4 and assessed whether SDF-1-induced activity could
be blocked by ola-PEG. Stimulation of Jurkat cells with human
SDF-1 resulted in a dose-dependent internalization of CXCR4.
The maximal effect was reached at around 3 nM, half-maximal
internalization was achieved at around 0.3 nM. Increasing
concentrations of ola-PEG inhibited SDF-1-mediated CXCR4
receptor internalization, with an IC50 of 200 pM (Figure 3B).
Also, ola-PEG inhibited SDF-1-mediated chemotaxis of
CXCR4-expressing Jurkat cells in a dose-dependent manner,
displaying an IC50 of 200 pM (Figure 3C). Additionally, using
a b-arrestin complementation assay with a CXCR7 reporter
cell line, we confirmed that ola-PEG also blocks SDF-1-depen-
dent activation of the second SDF-1 receptor CXCR7. At a
fixed concentration of 10 nM SDF-1 (EC50), the half-maximal
inhibition (IC50) was at 5.1 nM ola-PEG (Figure 3D). (Note that
for stoichiometric reasons, the assay does not allow measure-
ment of IC50 values lower than 5 nM.) A nonfunctional Spie-
gelmer with the reverse sequence showed no effects (data
not shown).Cell Reports 9, 118–128, October 9, 2014 ª2014 The Authors 119
Figure 1. SDF-1 Expression in Metastasized Bone Marrow Niches
(A) Bone marrow (BM) specimens were obtained from patients with multiple myeloma, MGUS, or solid tumors and stained with anti-SDF-1; MGUS samples were
double-stained for SDF-1 (brown) and CD138 (blue). Normal BM was used as control. P indicates p value.
(legend continued on next page)
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Figure 2. 193-G2-001/Olaptesed Secondary Structure and Binding
Kinetics
(A) Pull-down binding assay of aptamer D-193-G2-001, using the biotinylated
selection target D-SDF-1. Fitting with a three parameter algorithm revealed a
KD of 268 pM.
(B) Secondary structure prediction for olaptesed, with potential base pairs
forming three hydrogen bonds depicted in red, and those forming two
hydrogen bonds with each other shown in blue.
(C) Biacore analysis of ola-PEG binding to immobilized human SDF-1a, at
37C under physiological buffer conditions. Raw data: black; fitted data: red.
Figure 3. In Vitro Characterization of Ola-PEG
(A) CC, CXC, CX3C, and XC chemokines (2 mM) were checked for competing
with the binding of ola-PEG (12.5 nM) to immobilized human SDF-1a. As
expected, mixtures of ola-PEG with SDF-1a or SDF-1b competed fully, but
none of the other chemokines did so. Data are double referenced and are
plotted as mean response units ±SD of n = 2 injections.
(B) Inhibition of SDF-1a-induced CXCR4 receptor internalization by ola-PEG.
Jurkat cells were incubated with 0.3 nM SDF-1, plus various concentrations
of ola-PEG. CXCR4 surface expression was quantified by flow cytometry,
using a CXCR4 specific PE-labeled antibody. Data points are means ± SD for
triplicate measurements. ola-PEG inhibits CXCR4 internalization with an IC50
of approximately 200 pM.
(C) Inhibition of SDF-1-induced chemotaxis. Ola-PEG inhibits chemotaxis
of Jurkat cells, with an IC50 of approximately 200 pM. Baseline level (fluores-
cencemeasured without SDF-1) is reached at approximately 800 pM ola-PEG.
Means ± SD for triplicate measurements are shown.
(D) Inhibition of SDF-1-induced CXCR7 activation by ola-PEG. The mean IC50
value obtained from three independent experiments was 5.1 nM.Pharmacokinetics of Ola-PEG
Following a single subcutaneous (s.c.) administration of
10 mg/kg ola-PEG in mice, maximum plasma concentrations
(Cmax) of ola-PEG were observed at 12 and 6 hr in male and
female mice, respectively (tmax) (Table S2; Figure S2D). There-
after, the plasma concentrations of ola-PEG declined, with
a mean apparent half-life (t1/2) of 13 hr, which is comparable
to the value obtained after intravenous (i.v.) administration.
The bioavailability (F) of ola-PEG in male and female mice was
estimated to be approximately 29.8% and 39.8%, respectively,
with no appreciable or consistent gender-related difference
in systemic exposure (AUC and Cmax) to ola-PEG. Human phar-
macokinetics and pharmacodynamics, along with safety evalu-(B) SCID/Bgmice were injected (i.v.) with 53 106 MM.1S-GFP+ cells; after 3 week
mouse skull BM niches were imaged after 4 hr, using in vivo confocal microsco
green; vessels: red; AF633-anti-SDF-1a Ab: blue).
(C) Levels of SDF-1a in primary BM mesenchymal stromal cells isolated from
P indicates p value.ations, were performed in healthy volunteers in a clinical phase I
study (Vater, 2013): ola-PEG had a mean plasma half-life of
33–40 hr, and was safe and well tolerated up to the highest
dose of 10.8 mg/kg, when administered as a 15 min i.v. infusion.
ola-PEG mobilized white blood cells and hematopoietic stems, Alexa Fluor (AF) 633-conjugated anti-SDF-1a (Ab) was administered i.v., and
py. Evans Blue was used to visualize blood vessels (MM.1S-GFP+/Luc+ cells:
MM patients (n = 10) and healthy subjects (n = 5) were evaluated by ELISA.
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Figure 4. Ola-PEG-Dependent Neutralization of SDF-1 Reduces MM
Tumor Progression In Vivo
(A) Three weeks of pretreatment with ola-PEG (20 mg/kg injected every other
day; s.c.) led to inhibition of MM tumor progression, shown with use of
bioluminescence imaging. Ola-PEG-treated mice are compared to mice that
were pretreated with AMD3100 (5 mg/kg, daily; s.c.), or to untreated mice
(n = 8/group). Error bars indicate SD. P indicates p value.
(B) Ola-PEG-pretreated mice presented with prolonged survival relative to
AMD3100-pretreated or untreated mice (n = 10/group). P indicates p value.and progenitor cells, as shown by CD34+ cell counts and colony
formation assays.
Ola-PEG-Dependent Neutralization of SDF-1 Modulates
BM Niches and Inhibits Bone Engraftment and Bone
Colonization by MM Cells
To test the hypothesis that neutralization of SDF-1 in BM niches
makes them less receptive toMM cell engraftment and coloniza-
tion, we first examined whether ola-PEG-dependent SDF-1
inhibition prevents MM cell bone engraftment. MM cells were
injected (i.v.) into control untreated mice, or into mice that were
pretreated with ola-PEG (20 mg/kg; every other day) or with
AMD3100 (5 mg/kg; daily; s.c.); treatment was continued after
MM cell injection. Mice treated with ola-PEG showed significant
reduction of MM cell tumor growth, relative to mice that were
treated with AMD3100, or were untreated (Figure 4A), indicating
that ola-PEG-dependent modulation of the BM milieu delays
MM cell BM engraftment and tumor growth. Importantly, we de-
tected differences in survival with ola-PEG-treated mice display-
ing significantly improved survival compared to those treated
with AMD3100, or to untreated mice (Figure 4B). We next inves-
tigated whether ola-PEG treatment could also reduce MM cell
dissemination from a primary BM site to distant bones. MM122 Cell Reports 9, 118–128, October 9, 2014 ª2014 The Authorscell lines (murine or human) were loaded into bone chips and
implanted subcutaneously (s.c.) into recipient mice that were
pretreated with either vehicle control, or with ola-PEG. After
the implantation, ola-PEG treatment was continued in the mice
that were ola-PEG pretreated. Results showed that, compared
to control mice, SDF-1 neutralization by ola-PEG significantly
inhibited the colonization of distant BM sites by MM cells
(Figures 5A–5D). Importantly, no ola-PEG-mediated cytotoxic
effects were detected in MM cells in vitro (Figure S3A).
To better understand how BM niches are modulated by
neutralizing SDF-1, we examined ola-PEG-mediated transcrip-
tional changes in the BM microenvironment in vivo. SCID/Bg
mice were treated with ola-PEG (s.c. injection, 20 mg/kg, given
every other day) for 3 weeks. Untreated mice were used as con-
trols. At the end of the third week, BM was harvested, and gene
expression profiling was performed. Ola-PEG induced transcrip-
tional downregulation of its target SDF-1, reduced expression of
genes known to be regulators of angiogenesis, cell growth, cyto-
kine production, vessel development and integrin-mediated cell
adhesion, and downregulated protein kinase activity; in contrast,
heat-shock proteins were upregulated (Figure S3B; p < 0.05).
Genes were categorized using dChip software; see Supple-
mental Information for a detailed gene list.
To understand the in vivo distribution and localization of ola-
PEG in areas of MM cell growth, we injected (i.v.) mice that har-
bor MM.1S-GFP+ tumors with Alexa Fluor (AF) 647-conjugated
ola-PEG and used live confocal imaging to determine the spatial
localization of ola-PEG in BM niches that were colonized by
MM cells; results documented that ola-PEG penetrated into
BM areas that harbored MM cells (Figure S3C).
Ola-PEGMobilizes andChemosensitizes BM-Colonizing
MM Cells In Vivo
Because disruption of the SDF-1 gradient between BM and pe-
ripheral blood leads to the release of HSCs and lymphocytes into
the circulation (Bleul et al., 1996; Dalakas et al., 2005; Dar et al.,
2011; Kim and Broxmeyer, 1998; Kim et al., 1998), we argued
that SDF-1 neutralization may lead to the release of MM cells
from the BM into the peripheral circulation.
Whenmicewith establishedMMwere treatedwith ola-PEG for
5 weeks, we observed reduced numbers of MM cells within the
BM niches, along with increased numbers of MM cells in the cir-
culation (Figure S4A). These results indicate that ola-PEG has an
impact on the interaction of MM cells with the BM milieu in vivo,
leading to mobilization of MM cells. We therefore evaluated the
effect of ola-PEG as monotherapy, or as a combination therapy
with bortezomib, on tumor progression and MM cell dissemina-
tion in vivo. Control mice, andmice treatedwith ola-PEG as a sin-
gle agent, showed similar growth rates for MM.1S-GFP+/Luc+,
whereas mice treated with a combination of ola-PEG and borte-
zomib presented with a significant reduction of tumor burden;
this reduction was more pronounced when compared to mice
treated with bortezomib as a single agent (Figure 6A). These
data were supported by the finding that ola-PEG and bortezomib
work synergistically in inhibiting MM cell proliferation in vitro,
when tested on a panel of MM cell lines (Figures S5A–SD).
We next interrogated whether ola-PEG and bortezomib also
act synergistically in modulating MM cell dissemination to
Figure 5. Ola-PEG-Dependent Neutralization of SDF-1 Inhibits Dissemination of MM Cells from Bone-to-Bone
(A–D) Ola-PEG-dependent inhibition of SDF-1 inhibited in vivo colonization of MM cells (GFP+5TGM1; GFP+MM.1S), originating at a primary bone marrow site, to
distant bone niches, as demonstrated by flow cytometry (GFP+) and immunostaining for murine (m) and human (h)-CD138. H.E. indicates hematoxylin-eosin
staining (203; 403). Mice were euthanized when signs of paralysis were detected. Error bars indicate SD in (B) and (D). P indicates p values.distant BM niches in vivo, and, if so, whether this is due to the
ability of ola-PEG to modulate cell adhesion. In vivo confocal
microscopy revealed significant MM cell homing to the BM incontrol mice, whereas ola-PEG-treated mice presented with a
lower number of MM cells within the whole skull BM area that
was imaged (Figure 6B). These observations point to twoCell Reports 9, 118–128, October 9, 2014 ª2014 The Authors 123
Figure 6. In Vivo Relevance of Ola-PEG:
Effect on MM Tumor Growth
(A) SCID/Bg mice were injected (i.v.) with 5 3 106
MM.1S-GFP+/Luc+ cells. Subsequently, mice
were treated with vehicle (control), bortezomib
(0.5 mg/kg, twice/week; i.p.), or ola-PEG
(20 mg/kg, every other day; s.c.), alone or in
combination (ola-PEG followed by bortezomib)
(n = 5 per group). Tumor burden was detected by
bioluminescence imaging, at different time points
after MM cell injection (t0: second week; t1: fourth
week; t2: fifth week). Error bars indicate SD. P in-
dicates p value.
(B) Five weeks after MM cell inoculation, MM cell
presence in BM structures of the skull was evalu-
ated by intravital confocal microscopy (GFP+ MM
cells: green; Evans-Blue-positive blood vessels:
red). Specific BM niches are highlighted, and
relative magnification and 3D reconstruction are
provided for each panel.
(C) The presence of MM.1S-GFP+ cells ex vivo
on femur tissues was detected by immunofluo-
rescence. One representative image for one
mouse from each group is shown (403). For rela-
tive quantification, see Figure S5E.
(D) Primary MM BM-MSCs were treated with ola-
PEG for 10 hr and subsequently cultured in the
presence of MM.1S cells for 8 hr. MM.1S cells
were then harvested, and cell lysates were sub-
jected to western blotting, with use of antibodies
against p-ERK1/2, ERK1/2, p-cofilin, p-paxillin,
p-Akt, Akt, p-Src, p-S6R, p-GSK3, and tubulin.
MM.1S cells cultured in the absence of MM BM-
MSCs were used as control.
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possibilities: (1) that the BM of ola-PEG-treated mice is less
receptive to MM cells, and (2) that the reduction in number of
MM cells is due to an increase in mobilization of MM cells from
the BM into the peripheral blood. Analysis of bortezomib-treated
mice showed a significant reduction of MM cells, and this effect
was even more significant with the combination of ola-PEG and
bortezomib. These results were confirmed ex vivo, by quanti-
fying the presence of MM cells in the femurs of treatedmice (Fig-
ures 6C and S5E) and were further supported by the demonstra-
tion of synergism between ola-PEG and bortezomib in inhibiting
the adhesion of MM cells to primary MM BM-MSCs in vitro (Fig-
ures S6A–S6D).
The above findings were further corroborated at the protein
level: primary MM BM-MSCs were pretreated with ola-PEG
and subsequently cultured in the presence of MM cells; both
MM and BM-MSCs cells were then exposed to ola-PEG or bor-
tezomib, used alone or as a combinatory regimen. Ola-PEG in-
hibited the BM-MSC-dependent upregulation of p-ERK, p-Akt,
and p-Src in MM cells, and also similarly affected Akt-down-
stream-targeted proteins (Figure 6D). Notably, ola-PEG treat-
ment exerted a stronger effect when used in combination
with bortezomib: in particular, ola-PEG was able to overcome
the bortezomib-dependent activation of p-AKT, together with a
more pronounced inhibition of Akt-downstream-targeted pro-
teins (p-S6R; p-GSK3). In addition, proteins such as cofilin and
paxilin, which are involved in the modulation of cell adhesion,
were also modulated by the ola-PEG/bortezomib treatment
(Figure 6D).
DISCUSSION
In 1889, Stephan Paget presented the ‘‘seed-and soil’’ hypothe-
sis for cancer metastasis, which states that certain malignant
cells (seed) have a high and specific affinity for the milieu of spe-
cific organs (soil), and that the metastatic phenotype transpires
only when the tumor cell and the surrounding microenvironment
are compatible (Paget, 1889). In support of this hypothesis,
a growing body of evidence now points to an essential role
of the tumor microenvironment as a critical regulator of tumor
cell metastasis, which facilitates the homing and expansion of
the tumor clone from the primary neoplasm to distant organs
(Valastyan and Weinberg, 2011). Along these lines, the recep-
tivity of the BM milieu and its components is essential for tumor
cells that preferentially metastasize to the bones, as reported for
breast, prostate, and lung cancer (Bryden et al., 2002; Devys
et al., 2001; Karnoub and Weinberg, 2006–2007; Smith et al.,
2004). A key factor in this cell trafficking network within the BM
is the interaction of the chemokine SDF-1 (CXCL12) and its
receptor CXCR4 (Alsayed et al., 2007; Azab et al., 2009; Dar
et al., 2011).
The development of therapeutic agents that prevent or delay
metastasis has been hampered by many limitations and failures;
indeed, a number of antineoplastic agents that are effective
on primary tumor sites do not display the same ability to inhibit
the proliferation of disseminated cancer cells, and there is
a pressing need to develop novel therapeutic strategies that
disrupt the permissive metastatic niche and thus reduce the
capacity of cancer cells to home to and engraft in these areas.Agents such as bisphosphonates, anti-RANK, and TGF-b inhib-
itors such as LY2157299 show promising activity, but none
demonstrates significant clinical activity in preventing or delay-
ing metastases. Antiangiogenic molecules are implicated in in-
hibiting the process of metastasis; however, recent evidence
shows that such drugs may in fact paradoxically increase meta-
static potential, due to the induction of hypoxia within the tumor
mass (Ebos et al., 2009).
Here, we use MM as a model of bone-to-bone cell dissemina-
tion. We first demonstrate that SDF-1 colocalizes in areas of the
BM where metastasis occurs, not only in multiple epithelial tu-
mors, but also in advanced stages of MM. Indeed, by comparing
early precursor stages (such as MGUS) to late, disseminated
stages of advancedMM, we were able to document a significant
increase in SDF-1 levels in the BM with advanced disease.
We also report on the identification and characterization of ola-
PEG, a PEGylated L-RNA Spiegelmer that binds the chemokine
SDF-1 with high affinity and selectivity. Our cell-based studies
show that ola-PEG potently inhibits SDF-1 action, and thereby
affects downstream signaling in tumor cells. Most interestingly,
our data show that ola-PEG-dependent neutralization of SDF-1
modulates the premetastatic BM niche in vivo and thus inhibits
MM tumor progression and prolonged survival, compared
to AMD3100-treated mice. SDF-1 inhibition also affects the
BM gene expression signature by altering regulators of angio-
genesis, adhesion, and proliferation that collectively modify the
BM niche; significantly reduces the homing of injected MM cells
to the BM of SCID/Bgmice; and decreasesMMcell bonemetas-
tases in vivo.Whether these effects are due to inhibition of SDF-1
signaling in the tumor cell itself, or due to changes in the stroma
and its associated gene expression, has yet to be determined.
Nevertheless, our findings clearly document a therapeutic effect
of ola-PEG in aMMxenograft model of established disease. Ola-
PEG colocalizes in areas of high tumor burden within the BM and
disrupts the interaction of MM cells with the BM niches, as evi-
denced by its influence on diminishing tumor mobilization, hom-
ing, and growth within the BM niches. In addition, ola-PEG also
chemosensitizes MM cells to bortezomib, despite the fact that it
(ola-PEG) has no single-agent activity on the tumor cells, indi-
cating that the activity of ola-PEG is specific to the niche
and its interaction with SDF-1. Thus, combinations of ola-PEG
with other chemotherapeutic agents are also likely to lead to
synergistic effects.
In conclusion, our data suggest that the anti-SDF-1 Spie-
gelmer ola-PEG represents an agent that successfully targets
the interaction between BM niches and tumor cells, thereby
preventing or disrupting BM colonization byMMcells and poten-
tially also by other bone-metastasizing tumor cells.EXPERIMENTAL PROCEDURES
Cells
Primary BM-MSCswere obtained fromMMpatients: approval for these studies
was obtained from the Institutional Review Board of the Dana-Farber Cancer
Institute. Informed consent was obtained from all patients and healthy volun-
teers, in accordance with the Declaration of Helsinki protocol. BM-MSCs
were devoid of hematopoietic cells (CD34, CD138, CD45, CD14) and
were positive for markers (CD73+; CD90+; CD105+; CD106+) that indicate their
multipotent MSC phenotype, as previously reported (Roccaro et al., 2013).Cell Reports 9, 118–128, October 9, 2014 ª2014 The Authors 125
Luciferase (luc)-expressing MM.1S-GFP/luc cell lines were generated by retro-
viral transduction ofMM.1Swith thepGC-gfp/luc vector (kind gift ofDr. A. Kung,
Dana-Farber Cancer Institute). The MM cell lines MM.1S, RPMI.8226, OPM2,
andU266,were also used. Jurkat cellswereobtained fromDSMZ.GFP+5TGM1
cells were kindly provided by Dr. G.D. Roodman (Indiana University).
In Vitro Selection and Synthesis of Ola-PEG
The oligonucleotide sequence of ola-PEG (50-GCG UGG UGU GAU CUA GAU
GUA UUG GCU GAU CCU AGU CAG GUA CGC-30 ) was identified after 18
selection rounds, by screening a library of approximately 1015 different RNA
oligonucleotides (carrying a 34-nt-long random region) against biotinylated
human SDF-1 in the all-D-configuration. The affinity of RNA libraries and ap-
tamers to D-SDF-1 was determined by use of pull-down binding assays with
radioactively labeled RNA. All oligonucleotides were synthesized at NOXXON
PharmaAG, following standard synthesis protocols, and PEGylated Spiegelm-
ers were synthesized as described (Hoffmann et al., 2011).
Use of Surface Plasmon Resonance for Analyzing the Binding and
Selectivity of Interaction between Ola-PEG and SDF-1
Surface plasmon resonance (SPR) measurements were carried out at physio-
logical conditions on aBiacore 2000 system, with use of CM4 sensor chips and
immobilized SDF-1; a reference flow cell (activated and then blocked) on the
same sensor chip served as a control. Data were analyzed, and KDwere calcu-
lated with the BIAevaluation 3.1.1 software, using a modified Langmuir 1:1
stoichiometric fitting algorithm. Each measurement was done at least three
times on different days. Selectivity data were plotted using the Prism 5.04
software.
Cell-Based Assays for Ola-PEG Characterization
A detailed description of the methods is provided in the Supplemental
Experimental Procedures. Briefly, CXCR4 internalization was determined in
Jurkat cells using phycoerythrin (PE)-labeled anti-CXCR4 and flow cytometry.
CXCR7 signaling was analyzed with use of a b-arrestin complementation
assay and a reporter cell line. MAP-kinase activation was studied in
CHO-K1 cells transfected with a plasmid that codes for human CXCR4
(NM_003467.2); immunoblotting was performed with anti-MAP-K and anti-
phospho-MAP-K. Chemotaxis assays were carried out with Jurkat cells in
Corning Transwell plates (5 mm pores) for 3 hr. Prior to the addition of cells
to the upper compartment, SDF-1 and various concentrations of ola-PEG
were preincubated for 20–30 min in the lower compartment; migrated cells
were quantified with resazurin.
Pharmacokinetics of Ola-PEG
A detailed description of the pharamcokinetic data is provided in the Supple-
mental Experimental Procedures.
Reagents
Bortezomib was obtained from Hospital Pharmacy, diluted in DMSO, and
stored at 20C until use and then thawed and diluted in culture medium
immediately before use. The maximum final concentration of DMSO (<0.1%)
did not affect cell proliferation and did not induce cytotoxicity on the cell lines
tested (data not shown). AMD3100 was obtained from Sigma-Aldrich.
Immunoblotting
MMcells, cultured in presence or absence of SDF-1, were harvested and lysed
using lysis buffer (Cell Signaling Technology) supplemented with 5 mM NaF,
2 mM Na3VO4, 1 mM phenylmethanesulfonylfluoride, 5 mg/ml leupeptine,
and 5 mg/ml aprotinin. Whole-cell lysates were subjected to SDS-PAGE and
transferred to polyvinylidene fluoride membrane (Bio-Rad). Immunoblotting
was done with antibodies against phospho(p)-ERK, ERK, p-cofilin, p-Akt,
Akt, p-Src, p-S6R, p-GSK3, p-paxillin, p-cofilin, and a-tubulin (Cell Signaling
Technology).
ELISA
SDF-1 levels were determined with use of an SDF-1 ELISA (Human SDF-1
immunoassay, R&D Systems), according to the manufacturer’s protocol.126 Cell Reports 9, 118–128, October 9, 2014 ª2014 The AuthorsGene Expression Profile
Gene expression profiling was performed on murine BM, using the Mouse
Genome 430 2.0 Array (NCBI Gene Expression Omnibus [GEO] accession
number: GSE42257). Untreated (n = 3) and ola-PEG-treated (n = 3) mice
were compared, and differentially expressed genes were classified with use
of dChip software (1.5-fold change; p < 0.05): a detailed list of genes is pro-
vided in the Supplemental Information.
In Vivo Studies
SCID/Bg mice were used for all in vivo studies. Six week-old female SCID-Bg
mice (Charles River Laboratories) were treated, monitored, and sacrificed
in accordance with a protocol approved by the Dana-Farber Cancer Institute
Animal Care and Use Committee.
Intravital confocal microscopy was performed as reported (Colmone et al.,
2008; Roccaro et al., 2013), using a Zeiss 710 confocal system (Carl Zeiss
Microimaging) on an upright Examiner stand with a custom stage. Briefly, a
skin flap was made in the scalp to expose the underlying dorsal skull surface;
high-resolution images with cellular detail were obtained through the intact
skull, using a 103 0.45 numerical apeture (NA) Plan-Apo objective (Carl Zeiss
Microimaging). Images were acquired at multiple imaging depths (up to
250 mm from the skull surface) and were merged with use of a maximum inten-
sity z-projection. GFP was excited with the 488 nm line on an Argon laser.
Blood vessels were imaged using Evans Blue (Sigma-Aldrich) excited with a
633 nm laser. Emission signals were collected with use of the Zeiss internal
confocal Quasar detectors. To localize SDF-1 within the BM niches, SCID/
Bg mice were injected (i.v.) with 5 3 106 MM.1S-GFP+ cells. After 3 weeks,
Alexa Fluor (AF) 633-conjugated anti-SDF-1a (Ab) (Santa Cruz Biotechnology)
was administered i.v. (Colmone et al., 2008), and, 4 hr later, intravital confocal
microscopy was used to visualize mouse skull BM niches. Evans Blue was
injected i.v. to detect vessels.
To visualize tumor growth in vivo, mice were injected with 75mg/kg of Lucif-
erin (Xenogen); 3 min later, tumor growth was detected by bioluminescence,
using a Xenogen In Vivo Imaging System (Caliper Life Sciences), as reported
(Roccaro et al., 2009).
For the in vivo metastasis model, bone chips were loaded with either murine
(GFP+ 5TGM1) or human (GFP+ MM.1S) MM cells (2 3 106 cells/bone). Two
bones were implanted subcutaneously into SCID/Bg mice, which were pre-
treated with vehicle or ola-PEG (20 mg/kg; every other day; s.c.) for 3 weeks.
Mice were euthanized once signs of limb paralysis became evident. MM cells
were harvested from one host femur and evaluated by flow cytometry for GFP
positivity; the second host femur was used for immunostaining with murine
and human anti-CD138, to detect metastasized 5TGM1 and MM.1S cells,
respectively.
To evaluate the effects of the bortezomib and ola-PEG combinatory regimen
in vivo, SCID/Bgmice were injected (i.v.) with 53 106MM.1S-GFP+/Luc+ cells;
after 2 weeks, treatment was initiated with either vehicle (control), bortezomib
(0.5 mg/kg, twice/week; i.p.), ola-PEG (20 mg/kg, every other day; s.c.), or
a combination of ola-PEG and bortezomib (n = 5 per group). Tumor burden
was detected with use of bioluminescence imaging at different time points
following the MM cell injection. Six weeks after MM cell inoculation, intravital
confocal microscopy was used for a detailed evaluation of MM cell presence
in BM structures of the skull. Evans Blue was injected i.v. to visualize vessels,
and immunofluorescence was used to detect MM.1S-GFP+ cells ex vivo on
femur tissues; nuclei were stained using DAPI.
Tissue Immunofluorescence
Sections through the femurs of mice were immunostained as described
(Hsieh et al., 2012), to detect MM.1S-GFP+ cells. Nuclei were stained
with DAPI. Slides were analyzed on a fluorescence microscope (Nikon
TE2000-E; objective 403 plan fluor 0.75 NA). MM.1S-GFP+ cells were
counted in four separate fields per slide. Images were taken on a Hama-
matsu OrcaER camera, with NIS-Element software. ImageJ was used to
merge channels.
In Vitro Studies
DNA synthesis was assessed by [3H]-thymidine ([3H]-TdR; PerkinElmer)
uptake, as described (Roccaro et al., 2010; Sacco et al., 2011). Adhesion
of MM cells to primary MM bone marrow MSCs was evaluated by an in vitro
adhesion assay, using Calcein AM-labeling ofMMcells, with degree of fluores-
cence measured on a spectrophotometer (485–520), as described (Roccaro
et al., 2010). Migration of MM cells was evaluated as reported (Roccaro
et al., 2010).
SDF-1 Knockdown
SDF-1 knockdown in primary MMBM-MSCs was achieved with use of a tetra-
cycline-inducible pTRIPz-Turbo-RFP vector (Thermo Scientific) containing the
target sequence (clones 111678, 227310) or scramble control, according to
manufacturer’s specifications. Transduction efficiency was determined by
evaluating the proportion of cells expressing red fluorescent protein (RFP).
SDF-1 knockdown efficiency was validated by detecting levels of SDF-1 in
the conditioned medium of infected cells.
Statistical Analyses
Thep values for the in vitro assayswere based on t tests (two-tailed;a 0.05), and
areprovided foreachfigure.Drugsynergismwasanalyzedby isobologramanal-
ysis, using the CalcuSyn software program (Biosoft), as described (Roccaro
et al., 2008, 2010; Sacco et al., 2011). The Kaplan-Meier curve was obtained
using GraphPad Prism, and p values were calculated based on log-rank test.ACCESSION NUMBERS
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